Nintedanib ameliorates experimental pulmonary arterial hypertension via inhibition of endothelial mesenchymal transition and smooth muscle cell proliferation-Reference-Cited by-同舟云学术

Nintedanib ameliorates experimental pulmonary arterial hypertension via inhibition of endothelial mesenchymal transition and smooth muscle cell proliferation

Published:2019-07-24 Issue:7 Volume:14 Page:e0214697
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Tsutsumi Takeo,Nagaoka Tetsutaro^ORCID,Yoshida Takashi,Wang Lei,Kuriyama Sachiko,Suzuki Yoshifumi,Nagata Yuichi,Harada Norihiro,Kodama Yuzo,Takahashi Fumiyuki,Morio Yoshiteru,Takahashi Kazuhisa

Funder

Japan Society for the Promotion of Science

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference49 articles.

1. Pulmonary arterial hypertension: the clinical syndrome;YC Lai;Circ Res,2014

2. ASPIRE registry: assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre;J Hurdman;Eur Respir J,2012

3. Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis;AE Frost;Chest,2013

4. Platelet-derived growth factor signaling in the lung. From lung development and disease to clinical studies;N Noskovicova;Am J Respir Cell Mol Biol,2015

5. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension;F Perros;Am J Respir Crit Care Med,2008

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pirfenidone and nintedanib attenuates pulmonary artery endothelial and smooth muscle cells transformations induced by IL-11;European Journal of Pharmacology;2024-06

2. Pirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and Shadows;Pharmaceuticals;2024-05-30

3. Drugst.One — a plug-and-play solution for online systems medicine and network-based drug repurposing;Nucleic Acids Research;2024-05-23

4. Bibliometric analysis of the pirfenidone and nintedanib in interstitial lung diseases;Heliyon;2024-04

5. Effects of Nintedanib on the Lungs via NLRP3 in a Model of Lipopolysaccharide-induced Acute Lung Injury in Rats;Namık Kemal Tıp Dergisi;2024-03-01